Optimizing HER2 Positive Early Breast Cancer Management – Sherbrooke

bookLearning Objectives

  • To review updated evidence as it relates to early-stage/curative HER-2 positive breast cancer assessment and treatment
  • To integrate evidence and consensus into practical approaches for the management of HER-2 positive early breast cancer
  • Focus on the paradigm shift of treating HER2 positive breast cancer in the neoadjuvant setting, discuss escalation versus de-escalation of therapies



Monday, September 27, 2021


12:00 pm - 1:00 pm


Registration is complimentary and restricted to healthcare professionals. Please click the button below to complete the transaction:

personAbout the Faculty

Dr. Michel Pavic


Bio coming soon!

Reshma Mahtani

Dr. Reshma Mahtani


Reshma L Mahtani, DO, is the Director of Community Outreach, Co-Director of the Women’s Center in Deerfield Beach, and Associate Professor of Clinical Medicine at the University of Miami Sylvester Comprehensive Cancer Center. After completing her master of science degree in neuroscience at the University of Connecticut, Dr Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She did her internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship. Dr Mahtani has spoken nationally and internationally on breast cancer. She is an active researcher and has authored numerous papers on various aspects of breast cancer treatment. Her ongoing involvement in clinical trials includes serving as Sylvester’s principal investigator on several phase II and III clinical trials in breast cancer. She has served as a member of the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee, an institutional representative for NSABP, an editorial board member of Practice Updates, and a member of the editorial board of The Breast Journal.


This program has been made possible through unrestricted support from Knight Therapeutics.